The financial impact of hospital-acquired methicillin-resistant  Staphylococcus aureus: An incremental cost and cost-effectiveness analysis.
Published: 2006
Language: eng
Number of pages: 58
ISBN-13: 9780494211908
Description: Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging antibiotic-resistant pathogen in Canadian hospitals associated with significant costs. Nosocomial (hospital-acquired) transmission of MRSA occurs when infection control practices are poor and is largely preventable. In this study, patient specific hospitalization costs were obtained for a cohort of patients with nosocomial MRSA and a matched comparator group of uninfected patients to determine the incremental cost attributable to MRSA. The median total hospitalization cost per nosocomial MRSA patient (colonized and infected) was CAD $14 841, while the corresponding cost for uninfected comparators was $5844, which suggests an incremental cost of $8997 per nosocomial MRSA patient. The incremental cost to prevent a case of nosocomial MRSA was $19.77. The cost-effectiveness ratio can be improved by decreasing hospital length of stay. Should Canadian MRSA rates continue to increase, implementing MRSA control now will prove even more cost-effective in the future.
Notes: Source: Masters Abstracts International, Volume: 45-03, page: 1447.

Thesis (M.Sc.)--University of Toronto, 2006.

Electronic version licensed for access by U. of T. users.

ROBARTS MICROTEXT copy on microfiche.